, Volume 59, Supplement 2, pp 13–20 | Cite as

Pharmacoeconomic Considerations in the Management of Hypertension

  • Helios Pardell
  • Ricard Tresserras
  • Pedro Armario
  • Raquel Hernández del Rey
Review Article


Hypertension is highly prevalent in developed and developing countries (more than 30% of the adult population when a threshold value of 140/90mm Hg is selected). It constitutes one of the major cardiovascular risk factors and accounts for more than 5% of total deaths worldwide.

The economic impact of hypertension is enormous, representing $US23.74 billion in the US in 1995 and approximately $US1685 million in Spain in 1994. Direct costs amount to more than 50% of the total costs of hypertension, and almost 70% of these are attributable to drug treatment. Furthermore, hypertensive patients use medical services 50% more than normotensive individuals, and hypertension represents one of the 3 leading causes of visits to primary healthcare centres.

When considering the cost effectiveness of hypertension treatment, there is no doubt that it is cost effective in comparison with other interventions, although some controversies exist, mainly with respect to mild-to-moderate hypertension and to the long term versus short term benefits. The controversy about the absolute risk of hypertension influences the cost-effectiveness analysis.

Because of the limitations of the available cost-effectiveness analyses, it is currently impossible to recommend the use of any particular antihypertensive drug for all patients with hypertension. Consequently, the choice of antihypertensive in any patient should be guided by clinical experience and the recommendations of the present international guidelines.


  1. 1.
    Murray CJL, López AD, editors. The global burden of disease. Cambridge, MA: Harvard University Press, 1996Google Scholar
  2. 2.
    Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N EnglJ Med 1999; 340: 1881–7CrossRefGoogle Scholar
  3. 3.
    O’Brien E, Staessen JA. What is ‘hypertension’? Lancet 1999; 353: 1541–3PubMedCrossRefGoogle Scholar
  4. 4.
    Hypertension Control. Report of a WHO Expert Committee. WHO Technical Report Series 862. Geneva: World Health Organization, 1996Google Scholar
  5. 5.
    Pardell H, Armario P, Hernández R, et al. Hypertension. Epidemiology and cost of illness. Dis Manage Health Outcomes 1997; 1: 135–40CrossRefGoogle Scholar
  6. 6.
    World Health Organization, International Society of Hypertension. 1999 WHO-ISH guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83Google Scholar
  7. 7.
    Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571–6CrossRefGoogle Scholar
  8. 8.
    Merrill RM, Kessler LG, Udler JM, et al. Comparison of risk estimates for selected diseases and causes of death. Prev Med 1999; 28: 179–93PubMedCrossRefGoogle Scholar
  9. 9.
    Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and disatolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598–615PubMedCrossRefGoogle Scholar
  10. 10.
    Thorn T. The economic costs of cardiovascular diseases in the United States, 1990. Bethesda, MD: National Heart, Lung and Blood Institute, 1993Google Scholar
  11. 11.
    Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996; 156: 1926–35CrossRefGoogle Scholar
  12. 12.
    Schauffer H, D’ Agostino R, Kannel WB. Risk for cardiovascular disease in the elderly and associated Medicare costs: The Framingham Study. Am J Prev Med 1993; 9: 146–54Google Scholar
  13. 13.
    Badia X, Rovira J, Tresserras R, et al. The cost of arterial hypertension in Spain. Med Clin (Barc) 1992; 99: 769–73Google Scholar
  14. 14.
    Pardell H, editor. Phannacoeconomics of arterial hypertension. Madrid: Spanish Society of Hypertension/Spanish League against Arterial Hypertension, 1996Google Scholar
  15. 15.
    Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment. A review of methodological issues. Health Policy 1991; 19: 55–78CrossRefGoogle Scholar
  16. 16.
    Moser M. The cost of treating hypertension. Can we keep it under control without compromising the level of care? Am J Hypertens 1998; 11: 120S–7PubMedCrossRefGoogle Scholar
  17. 17.
    Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden: an empirical investigation in primary health care. Scand J Prim Health Care 1991; 9(3): 155–60PubMedCrossRefGoogle Scholar
  18. 18.
    Kawachi I, Malcolm LA. Treating mild to moderate hypertension. Cost-effectiveness and policy implications. J Cardiovasc Pharmacol 1990; 16 Suppl. 7: S126–8PubMedGoogle Scholar
  19. 19.
    Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–9PubMedCrossRefGoogle Scholar
  20. 20.
    Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. Phannacoeconomics 1995; 7: 242–50CrossRefGoogle Scholar
  21. 21.
    Mosterd A, D’Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340: 1221–7PubMedCrossRefGoogle Scholar
  22. 22.
    National Health Survey, 1995. Madrid: Ministry of Health and Consumer Affairs, 1996Google Scholar
  23. 23.
    Christiansen T, Pedersen KM, Harvald B, et al. A health economic investigation of the effect of treatment for hypertension. Odense: Odense University Research Report 6, 1987Google Scholar
  24. 24.
    Ménard J, Cornu PH, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992; 6: 447–58PubMedGoogle Scholar
  25. 25.
    Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47–54CrossRefGoogle Scholar
  26. 26.
    Prieto M, de Abajo FJ, Montero D, et al. Antihypertensive drugs use in Spain, 1985–1995. Med Clin (Barc) 1998; 110: 247–53Google Scholar
  27. 27.
    O’Brien B. Patterns of European diagnosis and prescribing. London: Office of Health Economics, 1984Google Scholar
  28. 28.
    OECD Health Data. Paris: Organization for Economic Cooperation and Development, 1997Google Scholar
  29. 29.
    The National High Blood Pressure Education program. Bethesda, MD: National Institutes of Health, 1988Google Scholar
  30. 30.
    Pardell H, Bohigas L. Economic perspective of the health problem of hypertension. In: Consulta SA, editor. International Society of Hypertension. 1988 Hypertension Yearbook. Barcelona: 1989 [Spanish edition]: 1–13Google Scholar
  31. 31.
    Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Phannacoeconomics 1996; 10: 460–6CrossRefGoogle Scholar
  32. 32.
    Russell LB. Cost-effectiveness of antihypertensive treatment. General considerations. Hypertension 1989; 13 (5 Suppl.): 1141–4CrossRefGoogle Scholar
  33. 33.
    MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 Suppl. 1: S99–118CrossRefGoogle Scholar
  34. 34.
    Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke and coronary heart disease. Pt 2. Effects of short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38PubMedCrossRefGoogle Scholar
  35. 35.
    Mancia G, Cattaneo BM, Omboni S, et al. Clinical benefits of a consistent reduction in blood pressure. J Hypertens 1998; 16 Suppl. 6: S35–9Google Scholar
  36. 36.
    Sytkowski PA, D’Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-tenn treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697–703Google Scholar
  37. 37.
    MacMahon S, Cutler JA, Stamler J. Antihypertensive drug treatment. Potential, expected, and observed effects on stroke and on coronary heart disease. Hypertension 1989; 13 (5 Suppl.): 145–50CrossRefGoogle Scholar
  38. 38.
    Tsevat J, Weinstein MC, Williams LW, et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83: 1194–201PubMedCrossRefGoogle Scholar
  39. 39.
    Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 1999; 28: 343–8PubMedCrossRefGoogle Scholar
  40. 40.
    Zanchetti A, Mancia G. Editors’ corner: strategies for antihy-pertensive treatment decisions: how to assess benefits? J Hypertens 1997; 15: 215–6PubMedGoogle Scholar
  41. 41.
    Madhavan S, Alderman MH. The potential effect of blood pressure reduction on cardiovascular disease. A cautionary note. Arch Intern Med 1981; 141: 1583–6PubMedCrossRefGoogle Scholar
  42. 42.
    Ménard J, Chatellier G. Mild hypertension: the mysterious viability of a faulty concept. J Hypertens 1995; 13: 1071–7PubMedCrossRefGoogle Scholar
  43. 43.
    Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14: 683–9PubMedCrossRefGoogle Scholar
  44. 44.
    MacMahon S. Guidelines for antihypertensive therapy. J Hypertens 1996; 14: 691–3PubMedCrossRefGoogle Scholar
  45. 45.
    Zanchetti A, Mancia G. Editors’ corner: benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14: 809–11Google Scholar
  46. 46.
    Robson J. Information needed to decide about cardiovascular treatment in primary care. BMJ 1997; 314: 277–80PubMedCrossRefGoogle Scholar
  47. 47.
    Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary prevention vs secondary prevention. Arch Intern Med 1998; 158: 655–62Google Scholar
  48. 48.
    Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329–35PubMedGoogle Scholar
  49. 49.
    Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47–54CrossRefGoogle Scholar
  50. 50.
    Zanchetti A. Cost-effectiveness of antihypertensive therapy: what message to patients and health services? J Hypertens 1998; 16 Suppl. 9: S21–3Google Scholar
  51. 51.
    Weinstein MC, Stason WB. Hypertension. A policy perspective. Cambridge, MA: Harvard University Press, 1976Google Scholar
  52. 52.
    Johannesson M, Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992; 1: 250–64PubMedCrossRefGoogle Scholar
  53. 53.
    Johannesson M, Borgquist L, Jönsson B, et al. The costs of treating hypertension an analysis of different cut-off points. Health Policy 1991; 18: 141–50PubMedCrossRefGoogle Scholar
  54. 54.
    Maynard A. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6: 417–20PubMedGoogle Scholar
  55. 55.
    Field K, Thorogood M, Silagy C, et al. Strategies for reducing coronary risk factors in primary care: which is most costeffective? BMJ 1995; 310: 1109–12PubMedCrossRefGoogle Scholar
  56. 56.
    UK Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720–6CrossRefGoogle Scholar
  57. 57.
    Stason WB. Cost and quality trade-offs in the treatment of hypertension. Hypertension 1989; 13 (5 Suppl.): I145–8PubMedCrossRefGoogle Scholar
  58. 58.
    Hilleman DE, Mohiuddin SM, Lucas D, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994; 16: 88–102PubMedGoogle Scholar
  59. 59.
    Stason WB. Opportunities for improving the cost-effectiveness of antihypertensive therapy. Am J Med 1986; 81 Suppl. 6C: S45–9CrossRefGoogle Scholar
  60. 60.
    Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199–208PubMedCrossRefGoogle Scholar
  61. 61.
    Dickerson JEC, Hingorani A, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008–13PubMedCrossRefGoogle Scholar
  62. 62.
    Ramsay LE, ul Haq I, Yeo WW, et al. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens Suppl. 1996; 14(5): S187–94PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Helios Pardell
    • 1
    • 2
  • Ricard Tresserras
    • 2
  • Pedro Armario
    • 1
  • Raquel Hernández del Rey
    • 1
  1. 1.Department of Internal Medicine, Hypertension UnitConsortium of the Red Cross HospitalBarcelonaSpain
  2. 2.CINDI-Catalonia ProgrammeMinistry of Health & Social Security, Autonomous Government of CataloniaBarcelonaSpain

Personalised recommendations